September 25th, 2026FDA Approves Belzutifan-Lenvatinib Combo for Advanced Kidney CancerFDA approved belzutifan plus lenvatinib for advanced ccRCC after PD-1/PD-L1 therapy, expanding treatment options for those with disease progression.Read more
September 25th, 2026Real-World Data Back Dupilumab's Long-Term Use in Pediatric ADA 3-year registry found dupilumab controlled atopic dermatitis (AD) in most children, though those under 6 years were likelier to stop treatment.Read more
September 25th, 2026Overactive Bladder Predictors in Women Extend Beyond Age, BMIMachine learning identified age, BMI, income, and reproductive factors as key predictors of overactive bladder risk among US women.Read more
September 25th, 2026AJMC® in the Press, September 25, 2026Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.Read more
September 25th, 2026Hospital Floor Hallway Boarding: A Systematic Review of OutcomesBoarding admitted patients on inpatient floor hallways can alleviate emergency department (ED) crowding. Outcomes tend to be positive, but the published evidence is weak, according to this systematic review.Read more
September 24th, 2026Surrogate End Points, Drug Costs Complicate Oncology FormulariesAccelerated approvals, surrogate end points, and high drug costs are reshaping cancer center formulary decisions, explained panelists at PCOC.Read more
September 24th, 202691% of Community Oncology Sites Offer Bispecifics Despite BarriersMost community oncology practices now administer bispecific antibodies in-office, but reimbursement gaps remain a top barrier, a survey finds.Read more
September 24th, 2026COVID-19, Measles, and the New Vaccine Order: What Parents Should KnowTammy Lundstrom, MD, JD, discusses the new childhood vaccine order, single-dose MMR access concerns, and the measles resurgence.Read more